title: Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives.
abstract: OBJECTIVE
  Patient satisfaction with disease control of systemic lupus erythematosus (SLE) is an important component of medical management. This analysis evaluated patient and physician satisfaction with disease control of SLE, factors associated with satisfaction/dissatisfaction, and the degree of physician-patient concordance of these parameters.
  
  
  METHODS
  Data were extracted from the US Adelphi Real World Lupus Disease Specific Programme®, a cross-sectional survey of 50 rheumatologists, 25 nephrologists, and their patients with non-nephritis SLE (NNSLE) or lupus nephritis (LN).
  
  
  RESULTS
  Physicians reported moderate or severe disease activity in 25.0% of patients with NNSLE and in 50.5% of patients with LN, and were satisfied with disease control in 78.6% (132/168) and 73.8% (152/206) of patients, respectively. For patients, 75.8% (75/99) with NNSLE were satisfied with their current treatment, compared with 65.5% (74/113) with LN. Physician-patient agreement (70.7%) on the level of satisfaction was "slight" (kappa =0.1445) for NNSLE; patients were more frequently dissatisfied than physicians with regard to joint tenderness, fatigue, anxiety, pain on movement, malar rash, and photosensitivity. Physician-patient agreement (71.4%) on the level of satisfaction was "fair" (kappa =0.3695) for LN; patients expressed greater dissatisfaction than physicians for headache, photosensitivity, and anxiety, whereas physicians were more dissatisfied with regard to joint swelling, kidney function, and blood pressure control. In general, patients with NNSLE or LN who were dissatisfied (or whose physicians were dissatisfied) were more likely to have joint swelling, joint stiffness, malar rash, hair loss, depression, and fatigue, have moderate or severe disease, or to be currently experiencing disease flare.
  
  
  CONCLUSIONS
  These data highlight the patient and physician dissatisfaction with real-world disease control of SLE.
authors: Clinical Development, AbbVie Inc., North Chicago, USA.
authors: Neelufar
authors: N
authors: Mozaffarian
authors: Adelphi Real World Ltd., Macclesfield, UK.
authors: Steve
authors: S
authors: Lobosco
authors: Clinical Development, AbbVie Inc., Worcester, MA, USA.
authors: Peng
authors: P
authors: Lu
authors: Adelphi Real World Ltd., Macclesfield, UK.
authors: Adam
authors: A
authors: Roughley
authors: Global Medical Affairs Immunology, AbbVie Inc., Madrid, Spain.
authors: Gabriela
authors: G
authors: Alperovich
keywords: agreement; concordance; disease control; lupus; satisfaction